Viatris Inc.
VTRS
Rang în acțiuni
#1096
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Preț acțiune
$18.55
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$21.31B
Schimbare (1 zi)
1.81%
Schimbare (1 an)
82.40%
Țară
US
Tranzacționează Viatris Inc. (VTRS)
Categorie
Healthcare
Marja operațională pentru Viatris Inc. (VTRS)
Marja operațională la October 2026 TTM: -0.59%
Conform celor mai recente rapoarte financiare și prețului acțiunilor Viatris Inc., marja operațională curentă (TTM) este -0.59%. La finalul anului 2023, compania avea o marjă operațională de 4.97%.
Istoricul marjei operaționale pentru Viatris Inc. din 2004 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | -0.59% | -942.86% |
| 2024 | 0.07% | -98.59% |
| 2023 | 4.97% | -49.95% |
| 2022 | 9.93% | -5,326.32% |
| 2021 | -0.19% | -89.20% |
| 2020 | -1.76% | -128.30% |
| 2019 | 6.22% | -21.46% |
| 2018 | 7.92% | -34.38% |
| 2017 | 12.07% | 91.28% |
| 2016 | 6.31% | -59.26% |
| 2015 | 15.49% | -11.59% |
| 2014 | 17.52% | 6.63% |
| 2013 | 16.43% | 0.67% |
| 2012 | 16.32% | -0.49% |
| 2011 | 16.40% | 23.87% |
| 2010 | 13.24% | 28.79% |
| 2009 | 10.28% | 77.24% |
| 2008 | 5.80% | -54.69% |
| 2007 | 12.80% | -44.01% |
| 2006 | 22.86% | -5.18% |
| 2005 | 24.11% | -33.03% |
| 2004 | 36.00% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -138.86% |
IN
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.